BOEHRINGER-INGELHEIM

Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO^® 1&2 trials (NCT01964352 /NCT02006732 ), which show Spiolto^® Respimat^® (tiotropium/olodaterol) provides consistent, clinically meaningful improvements in quality of life versus placebo in patients with COPD^* . These data are published online in the journal Respiratory Medicine .¹

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150817005379/en/

For COPD patients, breathlessness, among other symptoms, limits their ability to keep active and has a negative impact on their daily lives. As there is no cure for COPD, improving quality of life is a major goal of treatment. In COPD, quality of life is measured using the SGRQ^† ; a reduction in SGRQ score of 4 points or more is deemed clinically meaningful.² The OTEMTO^® trials show Spiolto^® Respimat^® provides a reduction in SGRQ total score of 4.67^‡ versus placebo.

“The improvement in quality of life provided by Spiolto^® Respimat^® in these trials could make a noticeable difference to the daily activity of COPD patients and enable them to maintain a more independent life,” said Dave Singh, Professor of clinical pharmacology and respiratory medicine, University of Manchester and lead investigator of the OTEMTO^® trials. “For example, this could mean that patients are able to walk up stairs without stopping, go out to socialise with friends or find it easier to wash and dress. Essentially, the data show that patients feel much better.”

Further data from the 1,600 patient OTEMTO^® trials show Spiolto^® Respimat^® provides:

• clinically meaningful improvements in breathlessness compared to placebo (measured by a 1.62 point improvement in TDI focal score^§ ), reflecting the meaningful quality of life benefits
• consistent improvements in lung function, breathlessness and quality of life compared to Spiriva^® (tiotropium)

• a safety profile similar to Spiriva^® or placebo. Incidence of adverse events (AEs) was broadly similar across treatment groups, with a higher incidence of AEs leading to discontinuation in the placebo groups compared to the treatment groups

OTEMTO^® 1&2 build on the pivotal phase III TONADO® trials that demonstrated Spiolto^® Respimat^® provides significant improvements in lung function, breathlessness, quality of life and reduction in rescue medication use over Spiriva^® Respimat^® right from the initial disease stages when patients first need maintenance therapy.^3,4 OTEMTO^® 1&2 are part of the >15,000 patient TOviTO^® Phase III clinical trial programme, one of the largest trial programmes conducted in COPD.

U.S. Food and Drug Administration (FDA) recently accepted for review a Supplemental New Drug Application (sNDA) to include the OTEMTO® quality of life data in the Stiolto™ Respimat^®** label.

For further information visit: http://newscentre.boehringer-ingelheim.com/education_hub1/respiratory.html

OTEMTO^® Respiratory Medicine publication: http://dx.doi.org/10.1016/j.rmed.2015.08.002

About Spiolto ^® Respimat ^®

To date, Spiolto^® Respimat^® has gained approval in more than 20 EU/EEA countries, the US, Canada and Australia for use in the treatment of patients with COPD.

Spiolto^® Respimat^® is built on tiotropium, the active ingredient in Spiriva^® - the world’s most prescribed COPD maintenance treatment with over 40 million patient years of real life experience across all COPD severities.⁵ It is enhanced by olodaterol^†† , a unique and effective long-acting beta2-agonist with a fast onset of action,⁶ specifically designed to complement the efficacy of Spiriva^® . Spiolto^® is delivered by Respimat^® , the only inhaler available that actively^‡‡ delivers a unique mist, meaning the patient just needs to breathe in naturally for the medication to go deep into the lungs.^7-13

Intended audiences

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For ‘Notes to Editors’ and ‘References’ please visit: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/17_august_2015_copd.html

^* Chronic obstructive pulmonary disease

^† St George’s Respiratory Questionnaire (SGRQ), a disease-specific patient-reported instrument that evaluates symptoms including frequency and duration of cough, wheezing and breathlessness

^‡ SGRQ total score after 12 weeks of treatment in the combined data set of the 2 replicate studies OTEMTO®1 and OTEMTO® 2

^§ Transition dyspnoea index focal score after 12 weeks of treatment in the combined data set

^** Spiolto® Respimat® is marketed as Stiolto™ Respimat® in the US and Inspiolto™ Respimat® in Canada

^†† Marketed as Striverdi® Respimat®

^‡‡ Respimat® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation

View source version on businesswire.com: http://www.businesswire.com/news/home/20150817005379/en/

Contact:

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr Kristin Jakobs
Phone: +49 151 6894 7444
Fax: +49 (6132) 77 6601
Email: press@boehringer-ingelheim.com
www.boehringer-ingelheim.com

Link:

Multimedia Gallery

ClickThru